AROMMP-7 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase II drugs for Idiopathic Pulmonary Fibrosis have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AROMMP-7’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AROMMP-7 overview
ARO-MMP7 is under development for the treatment of idiopathic pulmonary fibrosis (IPF). It targets matrix metalloproteinase 7 (MMP7). The drug candidate is a siRNA which is being developed based on targeted RNAi molecule (TRiM) platform. It is administered through inhalational route.
Arrowhead Pharmaceuticals overview
Arrowhead Pharmaceuticals (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Its pipeline products include ARO-APOC3, ARO-ANG3, Olpasiran, GSK-4532990, ARO-PNPLA3, ARO-RAGE, ARO-MMP7, ARO-MUC5AC, Fazirsiran, ARO-HB, ARO-DUX4 and ARO-DM1. Arrowhead product indications include hypertriglyceridemia, dyslipidemia, cardiovascular disease, nonalcoholic steatohepatitis, inflammatory, idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis, much-obstructive, alpha-1 liver disease, hepatitis b, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. The company operates lab facilities in San Diego, California and Madison, Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
For a complete picture of AROMMP-7’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
